A SPAC I Acquisition Corp.
Status: Deal Closed
U=S+(3/4)W+R
W=S@11.50
R=S/10
| IPO Proceeds, $M | $69.00M |
|---|---|
| IPO Date | Feb 15, 2022 |
| CEO | Claudius Tsang |
| Left Lead | Chardan |
| IPO Cash in Trust | 101.0% |
| SPAC Tenor | 12 + 8 + 6 |
| IPO Sector |
Technology
TMT sector in US and Asia (excluding China) |
| IPO Geography | Global |
| Target Company | NewGenIvf |
| Deal Announced | Feb 16, 2023 |
| Deal Size, $M | $50.00M |
| Deal Sector | Healthcare |
| Deal Geography | Asia |
| SEC Filings | www.sec.gov |
| Approval Vote | Mar 4, 2024 |
| Amendment Vote | Oct 9, 2023 |
| Closing Date | Apr 3, 2024 |
Formerly ASCA
NIVF
NIVFW
| Price | $0.62 |
|---|---|
| Last closing price | $0.57 |
| H/L, today | $0.54 / $0.67 |
| Volume, today | 1,654,157 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on A SPAC I Acquisition Corp.:
- Structure and cap table
- 4 directors & officers
- 42 filings and events
- 1 underwriters
- 6 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Claudius Tsang | 44 | Chief Executive Officer, Chief Financial Officer and Director |
| Abuzzal Abusaeri | 47 | Director |
| Giang Nguyen Hoang | 35 | Director |
| John Brebeck | 57 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Chardan | BR | 6,000,000 | units |
| 6,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.